Main Article Content


Preeclampsia is a multifactorial syndrome in pregnancy whose cause is still unknown. Several proangiogenic and antiangiogenic mediators such as Vascular Endothelial Growth Factor (VEGF) and Nitrite Oxide (NO) play important roles in preventing preeclampsia. VEGF can increase NO level that lowers maternal blood pressure, improves endothelial function and reduces placental hypoxia in preeclampsia. Recombinant VEGF 121 is expected to be an option in the prevention and treatment of preeclampsia. This experimental study used mice (Mus musculus) as the model. The objective of this study was to observe the effect of recombinant VEGF 121 in increasing the level of nitric oxide in mice (Mus musculus) model of preeclampsia. This was an experimental analytical study with Randomized Control Trial (RCT) design. The study enrolled 27 pregnant mice (Mus musculus) which met the restriction criteria divided into 3 groups. The first group (K1) were 9 normal pregnant mice. The second group (K2) were 9 pregnant mice of preeclampsia model without treatment. The third group (K3) were 9 pregnant mice of preeclampsia model receiving recombinant VEGF 121 therapy. The independent variable was the administration of recombinant VEGF 121 and the dependent variable was the serum NO level. Statistical analysis was performed by using anova statistics. NO level in the first group (K1) was 1.746±0.347, with minimum value of 1.00 µM, and maximum value of 2.28 µM, CI (1.479-2.013).  NO level in second group (K2) was 1.167±0.380, with minimum value of 0.64 µM, and maximum value of 1.94 µM, CI (0.875-1.460). NO level in the third group (K3) was 2.164±0.556, with minimum value of 1.56 µM, and maximum value of 5.96 µM, CI (1.842-2.486). With anova statistical test, there were significant differences between K1 group and K2 group (p value=0.004<0.05), K1 group and K3 group (p value=0.000<0.05) as well as K2 group and K3 group (p value=0.029<0.05). In conclusion, Recombinant VEGF 121 increased the level of nitric oxide in mice (Mus musculus) model of preeclampsia significantly.


Recombinant Vascular Endothelial Growth Factor 121 nitric oxide mice (Mus musculus) preeclampsia

Article Details

How to Cite
Soetrisno, S., Isharyadi, I., & Sulistyowati, S. (2017). THE EFFECT OF RECOMBINANT VASCULAR ENDOTHELIAL GROWTH FACTOR 121 ON NITRIDE OXIDE LEVEL IN MICE (Mus musculus) MODEL OF PREECLAMPSIA. Folia Medica Indonesiana, 53(3), 191–195.


  1. Anggraini ND (2015). The effect of recombinant VEGF 121 on histopathological image changes of placenta and fetal weight in mice (Mus musculus) model of preeclampsia
  2. Comiskey M, Warner CM, Schust DJ (2013). MHC molecules of the preimplantation embryo and tropho-blast. Available from http://www.ncbi.nlm.nih. gov/books/NBK6277/. Published 2013. Accessed September 21, 2016
  3. Damayanti PD, Sulistyowati S, Respati SH (2015). Differences of endothelin-1 serum (ET-1) and nitrit oxide (NO) among preeclmapsia late onset and and normal pregnancy. Obstetrics and Gynecology of Medical Faculty UNS/DR Moewardi Hospital Surakarta
  4. Duley L (2009). the global impact of pre-eclampsia and eclampsia. Semin Perinatol 33, 130-137. doi: 10.1053 /j.semperi.2009.02.010.
  5. Erdemoglu E, Ugur M and Erdemoglu E (2009). Plasma homocysteine and nitric oxide level in preeclampsia. Dep Obstet Gynecol Zekai Tahir Burak Women Heal Res Educ Hosp Ankara, Turkey A Turkish-German Gynecol Assoc; 10 26-9
  6. Hladunewich, Karumanchi L (2007). Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol 2, 543-549. doi: 10.2215 / CJN.03761106.
  7. Irawan D, Sulistyowati S, Edwin E, Obstetrics D (2016). Recombinant VEGF 121 can improve glome-rular endothelosis in pregnant mice model of Preeclampsia. Maj Ginekol Obstet, 24
  8. Li Z, Zhang Y, Ma JY, et al (2007). Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 50, 686-92
  9. Markham KB, Funai EF (2014). Pregnancy-related hypertension classification of hypertensive disorders. In: Robert K. Creasy, Robert Resnik, Michael F. Greene, Jay D. Iams CJL, Thomas R. Moore, eds. Creasy and Resnik's Maternal-fetal medicine: principles and practice, China, Elsevier Saunders, p 756-781
  10. Nakagawa T (2007). Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. Am J Physiol 292, F1665-F1672. doi: 10.1152/ajprenal.00495.2006
  11. Naljayan MV, Karumanchi SA (2013). New developments in the pathogenesis of preeclampsia. Adv Chronic Kidney Dis 20, 265-270
  12. Nirwanasari R, Sulistyowati S, Respati SH (2014). Intra uterine growth restriction: the role of vascular endothelial growth factor (VEGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) in its Pathogenesis, Surakarta, Universitas Sebelas Maret
  13. Prabowo W (2015). Effect of recombinant VEGF 121 on placenta growth factor (PlGF) in mice (Mus musculus) model of preeclampsia
  14. Roswendi A, Sulistyowati S, Respati SH, Kartika H (2014). Level of soluble human leukocyte antigen-G (sHLA-G), vascular endothelial growth factor (VEGF) and soluble fms-like tyrosin kinase-1 (sFlt-1) in preeclampsia . Maj Ginekol Obstet 22
  15. Saha T, Halder M, Das A, Das SK (2013). Role of nitric oxide, angiogenic growth factors and biochemical analysis in preeclampsia 50 462-466
  16. Schlembach D (2003). Preeclampsia - still a disease of theories. Fukushima J Med Sci 49, 69-115.
  17. Shah DM (2007). Preeclampsia: new insights. Curr Opin Nephrol Hypertens 16, 213-220
  18. Sibai BM. Preeclampsia and hypertensive disorders of pregnancy. In: Steven G. Gabbe, Jennifer R. Niebyl, Joe Leigh Simpson MD, Mark B. Landon MD, Henry L. Galan MD, Eric RM Jauniaux MD, PhD, Deborah A. Driscoll MD, Vincenzo Berghella MD and William A. Grobman MD M, ed. Elsevier Inc. Seventh Ed. Philadelphia: Elsevier Inc. 661-705. doi: 10.1016 / B978-0-323-32108-2.00031-7
  19. Sondakh JA, Sulistyowati S, Respati SH (2016). Recombinant vascular endothelial growth factor 121 decreases vascular cell adhesion molecule-1 in murine pre-eclampsia placenta model. Universa Med 35
  20. Steinberg G, Khankin E V., Karumanchi SA (2011). Angiogenic factors and preeclampsia. Semin Nephrol 31, 33-46. doi: 10.1016 / S0049-3848 (09) 70020-9.
  21. Sulistyowati S, Bachnas MA, Anggraini ND, et al (2017). Recombinant vascular endothelial growth factor 121 injection for the prevention of fetal growth restriction in a preeclampsia mouse model. J Perinat Med 45, 245–51. doi: 10.1515/jpm-2016-0149
  22. Wiyono BE, Sulistyowati S, Respati SH (2015). Angiogenic Factors Soluble FMS-Like Tyrosine Kinase-1 and Vascular Endothelial Growth Factor in Pregnant Women of 8-20 Gestational Weeks with Risk of Preeclampsia. J Kesehatan Reproduksi 2
  23. Woods AK, Hoffmann, Weydert, Butler, Zhou, Sharma (2011). Adenoviral delivery of VEGF 121 early in pregnancy prevents spontaneous development of pre-eclampsia in BPH / 5 Mice. Hypertension.2011 Jan; 57 (1): 94-102. Hypertension 57, 94-102